BRPI0811223A2 - Métodos para modular uma inflamação em um paciente, e para tratar, controlar, reduzir ou melhorar uma infecção ocular ou oftálmica e uma sequela inflamatória da mesma, uso de uma fluoroquinolona, e, composição farmacêutica. - Google Patents
Métodos para modular uma inflamação em um paciente, e para tratar, controlar, reduzir ou melhorar uma infecção ocular ou oftálmica e uma sequela inflamatória da mesma, uso de uma fluoroquinolona, e, composição farmacêutica.Info
- Publication number
- BRPI0811223A2 BRPI0811223A2 BRPI0811223-1A2A BRPI0811223A BRPI0811223A2 BR PI0811223 A2 BRPI0811223 A2 BR PI0811223A2 BR PI0811223 A BRPI0811223 A BR PI0811223A BR PI0811223 A2 BRPI0811223 A2 BR PI0811223A2
- Authority
- BR
- Brazil
- Prior art keywords
- fluorokinoline
- ameliorating
- inflammation
- modulating
- eye
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94315407P | 2007-06-11 | 2007-06-11 | |
| PCT/US2008/064336 WO2008154136A1 (en) | 2007-06-11 | 2008-05-21 | Compositions and methods for modulating inflammation using fluoroquinolones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0811223A2 true BRPI0811223A2 (pt) | 2014-10-29 |
Family
ID=39673477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0811223-1A2A BRPI0811223A2 (pt) | 2007-06-11 | 2008-05-21 | Métodos para modular uma inflamação em um paciente, e para tratar, controlar, reduzir ou melhorar uma infecção ocular ou oftálmica e uma sequela inflamatória da mesma, uso de uma fluoroquinolona, e, composição farmacêutica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080306038A1 (pt) |
| EP (1) | EP2170342A1 (pt) |
| JP (1) | JP2010529133A (pt) |
| KR (1) | KR20100021444A (pt) |
| CN (1) | CN101678032A (pt) |
| AU (1) | AU2008262118A1 (pt) |
| BR (1) | BRPI0811223A2 (pt) |
| CA (1) | CA2686833A1 (pt) |
| MX (1) | MX2009013123A (pt) |
| TW (1) | TW200904429A (pt) |
| WO (1) | WO2008154136A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010004366A (es) * | 2007-11-05 | 2010-05-05 | Bausch & Lomb | Materiales inmiscibles en agua como vehiculos para suministro de farmacos. |
| CN102114020B (zh) * | 2009-12-30 | 2016-04-20 | 北京德众万全医药科技有限公司 | 一种含有贝西沙星或其盐的药用组合物及其制备方法 |
| CN113559105B (zh) | 2014-01-29 | 2026-06-23 | 维奥姆治疗有限公司 | 抗性痤疮的治疗 |
| CN119587555B (zh) * | 2024-12-17 | 2025-12-19 | 江汉大学 | 依碳氯替泼诺作为nlrp3炎症小体激活抑制剂的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2613139B2 (ja) * | 1990-07-19 | 1997-05-21 | エスエス製薬 株式会社 | キノロンカルボン酸誘導体 |
| US6685958B2 (en) * | 2001-04-25 | 2004-02-03 | Insite Vision Incorporated | Quinolone carboxylic acid compositions and related methods of treatment |
| WO2003035066A1 (en) * | 2001-10-23 | 2003-05-01 | Celltech R & D Limited | 2-aminoquinolone derivatives for use as impdh inhibitors |
| WO2004097410A1 (en) * | 2003-04-30 | 2004-11-11 | Pfizer Products Inc. | Screening methods for cataractogenic risk |
-
2008
- 2008-05-21 AU AU2008262118A patent/AU2008262118A1/en not_active Abandoned
- 2008-05-21 BR BRPI0811223-1A2A patent/BRPI0811223A2/pt not_active IP Right Cessation
- 2008-05-21 MX MX2009013123A patent/MX2009013123A/es not_active Application Discontinuation
- 2008-05-21 CA CA002686833A patent/CA2686833A1/en not_active Abandoned
- 2008-05-21 US US12/124,578 patent/US20080306038A1/en not_active Abandoned
- 2008-05-21 CN CN200880019421A patent/CN101678032A/zh active Pending
- 2008-05-21 WO PCT/US2008/064336 patent/WO2008154136A1/en not_active Ceased
- 2008-05-21 JP JP2010511245A patent/JP2010529133A/ja not_active Withdrawn
- 2008-05-21 KR KR1020097025828A patent/KR20100021444A/ko not_active Ceased
- 2008-05-21 EP EP08769550A patent/EP2170342A1/en not_active Withdrawn
- 2008-05-28 TW TW097119746A patent/TW200904429A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080306038A1 (en) | 2008-12-11 |
| MX2009013123A (es) | 2010-01-15 |
| TW200904429A (en) | 2009-02-01 |
| JP2010529133A (ja) | 2010-08-26 |
| WO2008154136A1 (en) | 2008-12-18 |
| KR20100021444A (ko) | 2010-02-24 |
| EP2170342A1 (en) | 2010-04-07 |
| CN101678032A (zh) | 2010-03-24 |
| AU2008262118A1 (en) | 2008-12-18 |
| CA2686833A1 (en) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015205914B2 (en) | 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| EP3606570B8 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| BRPI0909749A2 (pt) | uso de fotoiniciador para fabrico de medicamento para tratamento do ceratocone, da ectasia e fortalecimento da córnea | |
| BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
| EP2407171A3 (en) | Compositions and methods for the treatment of ophthalmic disease | |
| HK1212240A1 (en) | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor | |
| EA201300272A1 (ru) | Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы | |
| CL2010001406A1 (es) | Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion. | |
| BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
| WO2010141648A3 (en) | Artificial tears and therapeutic uses | |
| ATE456369T1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
| EA200870396A1 (ru) | Лечение аллергических заболеваний глаз | |
| WO2011084366A3 (en) | Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions | |
| WO2009040420A3 (en) | Use of a monoterpene to increase tissue repair | |
| ATE535257T1 (de) | Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin | |
| WO2008054639A3 (en) | Use of a catechin or polyphenol to treat ocular diseases and infection | |
| MX342183B (es) | Suspension oftalmica para uso ocular. | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| WO2008136034A3 (en) | Ophthalmic compositions for the treatment of ocular hypertension and glaucoma | |
| WO2012097264A3 (en) | Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof | |
| BR112017015387A2 (pt) | composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra | |
| BR112012015386B8 (pt) | composição oftálmica tópica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |